Journal of Cystic Fibrosis
Volume 7, Issue 1 , Pages 68-78, January 2008

Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages☆☆

Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, 02215, Boston, MA, United States

Received 2 July 2006; received in revised form 6 April 2007; accepted 11 May 2007.

Abstract 

Background

Cystic fibrosis (CF) is characterized by an excessive inflammatory response in epithelial cells and macrophages. In CF mice, lung inflammation can be abrogated by oral treatment with docosahexaenoic acid (DHA). Since PPARs and LXRs are important regulators of inflammation and fatty acid metabolism in macrophages, we hypothesized that these pathways are dysregulated in CF macrophages and are corrected with DHA treatment.

Methods

Peritoneal macrophages were obtained from wild type and cftr−/− mice. LPS induced cytokine secretion and NFκB activity were analyzed with and without oral DHA treatment. The expression and activity of PPARα,γ, δ and LXRα were analyzed by RT-PCR and EMSA.

Results

LPS induced TNFα and IL-6 secretion and NFκB p65 activity were increased in CF macrophages. This was associated with low basal PPARγ expression and attenuated LPS induced induction of PPARδ, LXRα and ABCA1. DHA pretreatment in vivo decreased TNFα secretion and p65 activity, and increased PPARα and γ expression and function. The effects of DHA could be reproduced by PPAR agonists and blocked by a PPARα antagonist.

Conclusion

Impaired regulation of nuclear receptors may contribute to the abnormal LPS induced signaling in CF macrophages and is reversed by DHA.

Keywords: Cystic fibrosis mice, Nuclear receptors, Macrophages, Inflammation, Docosahexaenoic acid, Cytokines

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Data from this manuscript were presented at the North American Cystic fibrosis Conference 2004 in Anaheim, CA and 2005 in Baltimore, MD.

☆☆ Contract grant sponsor: The Wenner-Gren foundations (to CA), Contract grant sponsor: NIH (to SF); Contract grant nr: R01 DK52765; Contract grant sponsor: The Cystic Fibrosis Foundation (to SF).

PII: S1569-1993(07)00063-X

doi:10.1016/j.jcf.2007.05.004

Journal of Cystic Fibrosis
Volume 7, Issue 1 , Pages 68-78, January 2008